<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04233203</url>
  </required_header>
  <id_info>
    <org_study_id>C-302</org_study_id>
    <nct_id>NCT04233203</nct_id>
  </id_info>
  <brief_title>Faster Aspart on Insulin-pump Treated T1DM Patients</brief_title>
  <acronym>realFACI</acronym>
  <official_title>Effectiveness and Safety of Insulin Faster Aspart on Continuous Subcutaneous Insulin Infusion Treated Adult Type 1 Diabetes Mellitus Patients in Routine Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jesús Moreno Fernández</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Castilla-La Mancha</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Castilla-La Mancha Health Service</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational retrospective study about effectiveness and safety of insulin Faster Aspart on&#xD;
      continuous subcutaneous insulin infusion treated adult Type 1 Diabetes Mellitus (T1DM)&#xD;
      patients in routine clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cross-sectional retrospective analysis about effectiveness and safety of insulin Faster&#xD;
      Aspart on continuous subcutaneous insulin infusion treated adult Type 1 Diabetes Mellitus&#xD;
      (T1DM) patients in routine clinical practice.&#xD;
&#xD;
      All clinical variables are gathered from two EMR softwares (Mambrino XXI and Carelink Pro®).&#xD;
&#xD;
      Data analysis is conducted using SPSS (Chicago, IL) statistics software. Results are&#xD;
      presented as mean ± SD values or percentages. A paired Student's t-test or a Wilcoxon&#xD;
      signed-rank test were used for the analysis of differences. Comparisons between proportions&#xD;
      were analyzed using a chi-squared test. A P value &lt; 0.05 was considered statistically&#xD;
      significant.&#xD;
&#xD;
      The protocol was approved by the reference Castilla-La Mancha Public Health Institute Ethic&#xD;
      Committee. All participants provided written informed consent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2020</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MAGE</measure>
    <time_frame>3 months</time_frame>
    <description>Differences from basal to 3 months after Faster Aspart initiation on Mean Amplitude of Glucose Excursions (MAGE).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VCo</measure>
    <time_frame>3 months</time_frame>
    <description>Differences from basal to 3 months after Faster Aspart initiation Variation Coefficient (VCo).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>M100</measure>
    <time_frame>3 months</time_frame>
    <description>Differences from basal to 3 months after Faster Aspart initiation on M100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GRADE</measure>
    <time_frame>3 months</time_frame>
    <description>Differences from basal to 3 months after Faster Aspart initiation on Glycemia Risk Assessment Diabetes Equation (GRADE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>J-index</measure>
    <time_frame>3 months</time_frame>
    <description>Differences from basal to 3 months after Faster Aspart initiation on J-index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MODD</measure>
    <time_frame>3 months</time_frame>
    <description>Differences from basal to 3 months after Faster Aspart initiation on MODD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CONGA</measure>
    <time_frame>3 months</time_frame>
    <description>Differences from basal to 3 months after Faster Aspart initiation on CONGA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>3 months</time_frame>
    <description>Differences from basal to 3 months after Faster Aspart initiation on Hemoglobin A1C (HbA1C).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic frequency</measure>
    <time_frame>3 months</time_frame>
    <description>Differences from basal to 3 months after Faster Aspart initiation on hypoglycemic frequency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIR-TAR-TUR</measure>
    <time_frame>3 months</time_frame>
    <description>9. Differences from basal to 3 months after Faster Aspart initiation on time in range, time above range and time under range.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Other glycemic outcomes</measure>
    <time_frame>3 months</time_frame>
    <description>Other glycemic control differences from basal to 3 months after Faster Aspart initiation: capillary blood glucose, interstitial blood glucose, self-monitoring of blood glucose (SMBG) daily frequency, severe hypoglycemia frequency.</description>
  </other_outcome>
  <other_outcome>
    <measure>Weigh</measure>
    <time_frame>3 months</time_frame>
    <description>Differences from basal to 3 months after Faster Aspart initiation on weight</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin dose</measure>
    <time_frame>3 months</time_frame>
    <description>Daily insulin doses (basal and bolus) and bolus insulin daily frequency.</description>
  </other_outcome>
  <other_outcome>
    <measure>Local adverse effects</measure>
    <time_frame>3 months</time_frame>
    <description>Faster Aspart related local adverse effects: itchiness, stinginess, pain, erythema, weal.</description>
  </other_outcome>
  <other_outcome>
    <measure>Catheters problems</measure>
    <time_frame>3 months</time_frame>
    <description>Incidences on insulin-pump catheters: obstructions, deformations.</description>
  </other_outcome>
  <other_outcome>
    <measure>Catheter change frequency</measure>
    <time_frame>3 months</time_frame>
    <description>Insulin-pump catheter change frequency</description>
  </other_outcome>
  <other_outcome>
    <measure>Severe adverse effects</measure>
    <time_frame>3 months</time_frame>
    <description>Faster Aspart severe adverse effects: ketosis, diabetic ketoacidosis, death.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">48</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Faster Aspart</arm_group_label>
    <description>All T1DM adult patients attended in Ciudad Real General University Hospital and treated with CSII and insulin Faster Aspart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Faster Aspart</intervention_name>
    <description>Currently receiving Faster Aspart during 3 or more months.</description>
    <arm_group_label>Faster Aspart</arm_group_label>
    <other_name>Fiasp</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Insulin pump</intervention_name>
    <description>Currently receiving CSII therapy during 6 or more months.</description>
    <arm_group_label>Faster Aspart</arm_group_label>
    <other_name>Medtronic 640G</other_name>
    <other_name>Medtronic 670G</other_name>
    <other_name>T Slim X2</other_name>
    <other_name>Accucheck Insight</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult (≥18 years of age) T1DM patients on CSII with Faster Aspart attended to care in our&#xD;
        consults were eligible.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years of age.&#xD;
&#xD;
          -  Diagnosed of Type 1 Diabetes Mellitus.&#xD;
&#xD;
          -  Be attended in Ciudad Real General University Hospital.&#xD;
&#xD;
          -  Current treated with CSII (CSII cohort) during ≥6 months.&#xD;
&#xD;
          -  Current treated with insulin Faster Aspart during ≥3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Less than 18 years old.&#xD;
&#xD;
          -  Other types of diabetes mellitus.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Alberto Garcia Seco, RN</last_name>
    <role>Study Chair</role>
    <affiliation>Ciudad Real General University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Obispo Rafael Torija, St.</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Castilla-La Mancha Health Service</investigator_affiliation>
    <investigator_full_name>Jesús Moreno Fernández</investigator_full_name>
    <investigator_title>Endocrinology and Nutrition Service, MD, PhD Affiliation: Castilla-La Mancha Health Service</investigator_title>
  </responsible_party>
  <keyword>insulin pump</keyword>
  <keyword>Faster aspart</keyword>
  <keyword>insulin</keyword>
  <keyword>glycemic variability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

